Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090745 | 0.74 | CTSD (0.50) | CTSDHCAR1MEN1KMT2AATM | |
| SCHEMBL21090792 | 0.74 | CTSD (0.50) | CTSDHCAR1MEN1KMT2AATM | |
| SCHEMBL21090746 | 0.71 | CTSD (0.47) | CTSDHCAR1MEN1KMT2AATM | |
| SCHEMBL22717083 | 0.63 | ADORA2A (0.42) | — | |
| SCHEMBL21055841 | 0.61 | KDM4E (0.42) | MEN1KMT2AALOX15KDM4EALDH1A1 | |
| SCHEMBL394560 | 0.61 | DCPS (0.53) | — | |
| SCHEMBL4317637 | 0.61 | KDM4E (0.31) | KDM4E | |
| SCHEMBL731560 | 0.60 | CYP11B2 (0.52) | RPS6KB1ROCK1 | |
| SCHEMBL21311046 | 0.60 | RPS6KB1 (0.50) | OPRM1OPRD1OPRK1OGFRL1POLB | |
| SCHEMBL21310915 | 0.60 | RPS6KB1 (0.50) | OPRM1OPRD1OPRK1OGFRL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | claimed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | claimed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CTSD 4473/4885HCAR1 3320/4885MEN1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.